Autoimmune conditions

Lupus (systemic lupus erythematosus)

If you or someone you love has just heard this diagnosis, start here. This guide explains what the condition is, how it is usually treated and whether a transplant plays any part.

Lupus (systemic lupus erythematosus, or SLE) is a long-lasting autoimmune disease that can affect the skin, joints, kidneys, blood and other organs. Most people are treated with medicines, starting with hydroxychloroquine. A transplant of the person’s own stem cells is uncommon, is used only for a few severe, hard-to-treat cases in specialized centers or research, and does not use a donor.

Other names and abbreviations

SLE, lupus, systemic LE, Disseminated lupus erythematosus, Systemic lupus

In short

  • Systemic lupus erythematosus, or lupus, is an autoimmune disease. It can affect the skin, joints, blood, kidneys, nervous system and other organs.
  • Treatment depends on how active it is and which organs are affected. It can include antimalarial medicines, immune-calming medicines and biologic treatments.
  • A transplant of the person's own stem cells is an uncommon option for some severe, hard-to-treat cases. It is a specialist or research option and needs no donor.
Jump to a section

Underlined words open a short explanation. See all terms

Where transplant fits

is an uncommon specialist or investigational option for selected severe . It uses the patient’s own and does not require a registry donor. and treatment-related harm remain concerns.

Treatment depends on the exact diagnosis, disease stage, prior treatment and the person’s health.

Key facts

Who it affects
Can affect children and adults and is more common in women. Demographic patterns do not determine an individual’s disease severity or treatment.
How common
About 73 in every 100,000 people, or an estimated 204,000 peoplePeople meeting the 1997 ACR lupus criteria in the United States; rate pooled from four state registries in the CDC National Lupus Registry network (cases found in 2002–2004 or 2007–2009), with the number estimated for 2018; about 9 times more common in women than men Source: How common
Cells used in a transplant
When performed, transplantation uses the patient’s own blood-forming stem cells, usually collected from peripheral blood.
Where a donor fits
Limited transplant role

The condition

What it is

Lupus is an autoimmune disease. The immune system, which normally fights germs, attacks the body’s own tissues instead. lupus erythematosus is the most common type, and “systemic” means it can affect many parts of the body.

Lupus looks different from person to person. Some people have mostly skin and joint problems, while others have inflammation in the kidneys, blood or nervous system. No single test diagnoses lupus, so doctors combine symptoms, an exam and blood tests such as the antinuclear (ANA) test.

What causes it

The exact cause is not known. Experts think certain genes, together with things around us such as viral infections, sunlight, some medicines and smoking, can set it off. Problems with how the body clears away damaged or dead cells may also play a part.

Lupus can run in families, and having a relative with lupus or another autoimmune disease raises the risk. It is not contagious, so no one can catch it from another person. According to the US National Institutes of Health, women get lupus about nine times more often than men, and it most often starts between ages 15 and 45. In a 2021 study that pooled US lupus registries run with the Centers for Disease Control and Prevention, lupus was most common in American Indian and Alaska Native people and in Black people, followed by Hispanic people.

Symptoms and effects

Common problems include painful, swollen joints, a “butterfly” rash across the cheeks and nose, and deep tiredness. Symptoms often come in flares, with calmer times in between. Sunlight can set off a flare in some people.

Lupus can also cause inflammation in the kidneys, called lupus nephritis, which can lead to kidney failure. It can lower blood counts, cause blood clots and affect the heart, lungs, brain and nerves. Which organs are involved shapes the treatment a person needs.

Where lupus (systemic lupus erythematosus) can affect the bodyLupus can affect many parts of the body, and which ones shapes the treatment a person needs.Simplified illustration.

A simple drawing of a body. Often affected: kidneys, skin and joints. Can also be affected: brain and spinal cord, airway and lungs, heart, nerves and blood vessels.

Often affected

  • Kidneys: lupus nephritis
  • Skin: a “butterfly” rash across the cheeks and nose
  • Joints: painful, swollen joints

Can also be affected

  • Brain and spinal cord
  • Airway and lungs
  • Heart
  • Nerves
  • Blood vessels: blood clots

This shows the parts of the body the condition can affect. Most people have only some of these, and the drawing says nothing about how severe any of them will be.

Diagnosis and treatment

How lupus is diagnosed

No single test can prove lupus. A doctor puts together a person’s symptoms, health and family history, a physical exam and lab results. The first blood test is usually the antinuclear antibody (ANA) test. Almost everyone with lupus has a positive ANA. But a positive ANA on its own does not mean a person has lupus, because healthy people can test positive too.

If the ANA is positive, doctors often check for antibodies that are more specific to lupus, such as anti-double-stranded DNA (anti-dsDNA) and anti-Smith. They may also test for antiphospholipid antibodies, which can cause blood clots in people with lupus. Blood counts, chemistry tests and a urine test for protein look for effects on the blood and kidneys. Sometimes a small sample (biopsy) of skin or kidney is checked under a microscope. Most people see a rheumatologist, a doctor who treats joint and autoimmune diseases, for their lupus care.

Because lupus symptoms come and go and can look like other illnesses, reaching a diagnosis can take time. A 2025 review of 25 studies found adults waited a median of about 18 months from first symptoms to diagnosis. For children, a 2025 review of 24 studies found an average of about 3.5 months. Studies measure this wait in different ways. In a German survey of 585 people with lupus, those who waited longer for a diagnosis reported more disease activity and more damage from the disease.

Researchers use the 2019 EULAR/ACR classification criteria to decide who counts as having lupus in studies. The criteria require a positive ANA at least once, then add points for symptoms and lab findings; 10 or more points classifies lupus.

How it is treated

Treatment depends on how active the lupus is and which organs are affected. International recommendations from EULAR, updated in 2023, advise hydroxychloroquine, a medicine first used for malaria, for all people with lupus. Steroids are used to calm flares, with the aim of lowering them to a small dose or stopping them when possible.

Other immune-calming medicines, such as methotrexate, azathioprine or mycophenolate, are often added. Biologic medicines, such as belimumab and anifrolumab, block specific parts of the immune response. For active kidney disease, doctors may use mycophenolate or cyclophosphamide, sometimes with belimumab or voclosporin, and rituximab may be considered when lupus does not respond.

A is not part of usual lupus care. In this own-cell (autologous) transplant, doctors collect the person’s blood-forming stem cells, give strong chemotherapy and immune-suppressing drugs, then return the stored cells so a new immune system can grow. European transplant experts (EBMT, 2025) describe it as an option for carefully selected people with severe lupus that has not responded to other treatment, after careful weighing of risks and benefits.

A European registry study, reported in 2013, looked at 28 people with hard-to-treat lupus who had this transplant at 8 centers between 2001 and 2008. By five years, an estimated 56% had lupus come back, and about 15% had died from complications such as infection rather than from lupus. CAR-T cell treatments, usually made from a person’s own immune cells, are being tested in clinical trials for lupus. They are a different treatment and are not yet standard care.

How lupus (systemic lupus erythematosus) can be treatedTreatment depends on how active lupus is and which organs are affected.Simplified illustration.

Kinds of treatment described for lupus (systemic lupus erythematosus): supportive care, medicines, a transplant with the person’s own cells (for a few people) and clinical trials.

After diagnosis, the options described here

  • Supportive care

    Care also includes steps to prevent infections, bone thinning and heart disease.

  • Medicines

    Hydroxychloroquine is advised for everyone with lupus, with steroids, immune-calming medicines and biologics added as needed.

  • Transplant with the person’s own cells, For a few people

    A transplant with the person’s own cells is used only for a few severe, hard-to-treat cases.

  • Clinical trials

    CAR-T cell treatments are being tested in clinical trials for lupus and are not yet standard care.

These are the kinds of treatment this page describes, not a plan. Which ones fit, in what order and whether they are combined differs from person to person.

Daily life and the donor’s role

Living with the condition

Lupus is usually lifelong, with ups and downs. Regular checkups with blood and urine tests help catch flares and kidney problems early. Warning signs of a flare can include more tiredness, joint swelling, pain, rash, fever, belly pain or headache.

Protecting the skin from the sun, staying active, managing stress and getting support can all help. Care also includes steps to prevent infections, bone thinning and heart disease. Patient groups offer education and support for people with lupus and their families.

For the few people who have a transplant, the process includes collecting stem cells, a hospital stay for and a recovery period with a high risk of serious infection. It is done at centers experienced in treating autoimmune disease with transplants, often as part of research.

The donor’s role

Lupus is not usually treated with a . When a stem cell transplant is used for lupus, it is almost always autologous, which means the cells come from the person’s own body. No registry donor is involved, and no donor search is needed.

In their 2025 recommendations for adults, European transplant experts (EBMT) listed a donor transplant from a matched brother or sister as developmental for lupus, meaning more research is needed. They listed transplants from unrelated or partly matched donors as generally not recommended. For most people living with lupus, joining a donor registry is a way to help other patients rather than a need of their own.

Looking ahead

Looking ahead

Outlook for lupus

Lupus is usually lifelong, and there is no cure. Still, with treatment many people manage the disease well, with times of wellness () between flares. Survival improved a great deal from the 1950s to the mid-1990s and has held steady since. Today most people with lupus in high-income countries live many years after diagnosis.

Several things shape each person’s outlook. Which organs are involved matters. Kidney disease (lupus nephritis) can lead to kidney failure. Where a person lives matters too: survival is lower in low- and middle-income countries, especially for children. A CDC-supported study in two Georgia counties followed people with lupus through 2016. Black people with lupus died, on average, more than 10 years younger than White people with lupus.

About these numbers. Each one says which group of people it comes from, and the place and years where the source gives them. It describes what happened across that group, not what will happen to any one person. And a figure measured among people who had a transplant is not the same as the number of people who need one.

  • About 89%10-year survival, adults with lupus

    Pooled estimate from cohort studies of adults with lupus in high-income countries, studies from 2008–2016 (worldwide review published 2017); about 85% in low- and middle-income countries

    Read the source: 10-year survival, adults with lupus
  • About 97%10-year survival, children with lupus

    Pooled estimate from cohort studies of children with lupus in high-income countries, studies from 2008–2016 (worldwide review published 2017); about 79% in low- and middle-income countries

    Read the source: 10-year survival, children with lupus
  • About 11%5-year risk of kidney failure, adults with lupus nephritis

    Adults with lupus kidney disease in high-income countries, pooled from cohort studies and trials published 1971–2015 (review published 2016); the risk fell from 16% in the 1970s to 11% by the mid-1990s, then held steady

    Read the source: 5-year risk of kidney failure, adults with lupus nephritis

These numbers describe large groups over time. They cannot predict what will happen to any one person.

Common questions

What is the life expectancy for someone with lupus?

Most people with lupus today live for many years after diagnosis. A large review pooled studies from 2008 to 2016. In high-income countries, about 89 in 100 adults and 97 in 100 children were alive 10 years after diagnosis. Survival was lower in low- and middle-income countries, especially for children. A CDC-supported study in two Georgia counties found that Black people with lupus died, on average, more than 10 years younger than White people with lupus. Kidney disease can lead to kidney failure, which is one reason regular urine tests matter. These are group numbers. They cannot say what will happen to one person.

Can a stem cell transplant cure lupus?

It is not a proven cure, and it is rarely used. The transplant uses the person’s own stem cells (autologous), so no donor is needed. European transplant experts (EBMT, 2025) list it as a clinical option for carefully selected people with severe lupus that has not responded to other treatment. In a European registry study of 28 people treated between 2001 and 2008, about 81 in 100 were alive five years later. But lupus came back in more than half, and some people died from complications such as infection.

Is CAR-T cell therapy a cure for lupus?

It is too early to say. CAR-T therapy changes a person’s own immune cells (T cells) so they remove B cells, which help drive lupus. In a 2024 report from Germany, 8 people with severe lupus each had one CAR-T infusion after a short course of chemotherapy. All 8 reached remission and were able to stop their immune-suppressing medicines. Side effects were mostly mild. But this was a very small group, and the whole study of 15 people with autoimmune diseases was followed for a median of 15 months. European transplant experts (EBMT, 2025) class CAR-T for lupus as developmental, meaning more trials are needed.

What blood tests show lupus?

No single blood test proves lupus. The antinuclear antibody (ANA) test usually comes first. Almost everyone with lupus has a positive ANA, but a positive result alone does not mean a person has lupus. When the ANA is positive, doctors often check more specific antibodies, such as anti-double-stranded DNA (anti-dsDNA), anti-Smith and antiphospholipid antibodies. Blood counts, chemistry tests and urine tests look for effects on the blood and kidneys. Levels of complement proteins in the blood are also part of the 2019 international classification criteria for lupus.

How often does lupus affect the kidneys?

Often. According to the NIH kidney institute (NIDDK), as many as 5 in 10 adults with lupus, and 8 in 10 children with lupus, have kidney disease. This is called lupus nephritis. To find it, care teams test urine for protein and blood, and test blood for creatinine, a waste product the kidneys clear. A kidney biopsy, a tiny sample of kidney tissue, confirms it and shows how the kidney is affected. NIDDK says 10 to 30 in 100 people with lupus nephritis develop kidney failure, which is why kidney checks are a regular part of lupus care.

Can children get lupus?

Yes. Lupus most often starts between ages 15 and 45, but it can begin in childhood. Children with lupus are more likely than adults to have kidney disease: about 8 in 10 children, compared with up to 5 in 10 adults. A 2025 review of 24 studies found that children waited an average of about 3.5 months from first symptoms to diagnosis. In high-income countries, most children with lupus now live for many years. Survival is lower in low- and middle-income countries.

Why the details matter

Early transplant studies have not shown that it works better than today’s medicines. Newer immune-cell therapies and own-cell transplant are different approaches, and neither is a routine cure.

How a transplant using your own cells works

For your next appointment

Lupus (systemic lupus erythematosus)

From the Jada Bascom Foundation disease library, jadabascomfoundation.org. Printed .

Questions to bring to your care team

  • Which lupus antibodies did my tests find, such as anti-dsDNA or antiphospholipid antibodies, and what do they mean for my care?
  • Which organs are affected right now, and how often will you check my urine and blood for kidney involvement?
  • Would a kidney biopsy help, and how would the result change my treatment?
  • Is CAR-T cell therapy being studied for lupus like mine, and how would it compare with the treatment I have now?
  • What is the exact name of the diagnosis or subtype, and what does it mean for treatment?
  • What is the goal of each treatment you are suggesting?
  • What would make a transplant worth considering later on?
  • Are there clinical trials that might fit?
  • Where can our family find support during treatment?

A one-page list to take to the next appointment, with room for notes.

Supporting someone with a diagnosis

We respect your privacy. Unsubscribe anytime.

Support for patients and families

These independent organizations offer information and support. JBF is not affiliated with them.

Sources and further reading

  1. Lupus
    NIAMS, NIH, Accessed 2026-09-05
  2. Autoimmune Disease
    EBMT Handbook, 2024-04-11
  3. 2025 EBMT practice recommendations for transplantation and CAR-T
    EBMT, 2025
  4. Systemic Lupus Erythematosus (Lupus): Diagnosis, Treatment, and Steps to Take
    NIAMS, NIH, Last reviewed October 2022
  5. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
    EULAR, Annals of the Rheumatic Diseases, 2024-01-02
  6. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry
    EBMT, Lupus, 2013
  7. What is lupus?
    Lupus Foundation of America, Accessed 2026-09-24
  8. Lupus
    MedlinePlus, US National Library of Medicine, Last updated 2026-08-11
  9. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries
    Arthritis & Rheumatology (Izmirly PM, et al.), 2021-04-23; accessed 2026-09-26
  10. Systemic lupus erythematosus
    MedlinePlus, US National Library of Medicine, Reviewed 2025-01-28
  11. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
    Arthritis & Rheumatology (EULAR/ACR), 2019-09
  12. Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review
    Rheumatology (Oxford), 2025-11-01
  13. Delay in Referral, Diagnosis, and Treatment in Pediatric Patients With Juvenile Systemic Lupus Erythematosus: A Systematic Review
    Journal of Clinical Rheumatology, 2026-01 (online 2025-10-02)
  14. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort
    Lupus, 2021-03
  15. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016
    Annals of the Rheumatic Diseases, 2017-12
  16. People with Lupus
    US Centers for Disease Control and Prevention, Last updated 2024-05-15
  17. Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016
    CDC, Morbidity and Mortality Weekly Report, 2019-05-10
  18. Lupus Nephritis
    NIDDK, NIH, Last reviewed January 2017
  19. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis
    Arthritis & Rheumatology, 2016-06
  20. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up
    New England Journal of Medicine, 2024-02-22

This information explains a condition and its treatments. It cannot diagnose an illness or recommend treatment for an individual. Your care team can explain how the evidence applies to you. Written and source-checked by the Jada Bascom Foundation. Each page lists the published sources it draws on.

Ways to help

Help another family understand.

Most people with lupus (systemic lupus erythematosus) are treated without a registry donor. A clear explanation can help the next family who hears this diagnosis, and many people with other blood cancers and blood disorders need a donor who is a stranger.

Learn and share

Most families meet these words for the first time at a diagnosis. Passing on a plain, sourced explanation is a real help.

Support this work

Gifts to the Jada Bascom Foundation support donor-awareness education like this page, community outreach, drive planning and referrals to official registries.

Join the registry

JBF points you to the official registry that serves your country. It explains who can join and what donation involves.

More in the library

Keep learning